CClinicalTrials.gg
CompletedNCT00342277Updated Feb 24, 2023

Microarray Expression Profiling to Identify Stereotypic mRNA Profiles in Human Parturition

An observational study in Preterm Birth and Premature Rupture of Membranes, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Completed at 4 sites in 4 countries. Per ClinicalTrials.gov, last updated 2023-02-24.

Sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
6,838
Sex
All
01

Study summary

The understanding of the biological mechanisms underlying preterm birth is very limited, making prevention of preterm birth difficult. The incidence of preterm birth worldwide varies between 6%-11% in singleton pregnancies, and 64-93% of preterm deliveries occur after the spontaneous onset of labor (preterm labor). The risk factors associated with preterm birth include demographic variables such as ethnic group, past obstetric history, and complications of the current pregnancy such as infection and fetal congenital anomalies. The current study aims to investigate the basic mechanisms of preterm labor by systematically cataloging the changes in expression levels of all expressed genes whose sequences are available. The goals will be accomplished by using microarray technology followed by subsequent confirmative or complementary analyses.

Read the detailed description

The understanding of the biological mechanisms underlying preterm birth is very limited, making prevention of preterm birth difficult. The incidence of preterm birth worldwide varies between 6%-11% in singleton pregnancies, and 64-93% of preterm deliveries occur after the spontaneous onset of labor (preterm labor). The risk factors associated with preterm birth include demographic variables such as ethnic group, past obstetric history, and complications of the current pregnancy such as infection and fetal congenital anomalies. The current study aims to investigate the basic mechanisms of preterm labor by systematically cataloging the changes in expression levels of all expressed genes whose sequences are available. The goals will be accomplished by using microarray technology followed by subsequent confirmative or complementary analyses.

02

Conditions studied

  • Preterm Birth
  • Premature Rupture of Membranes

Keywords

  • Genetic Risk Factors
  • Tissue Specific Expression
  • Quantitative Real Time PCR
  • Preterm Birth
  • Expression Profiling
  • Natural History
03

In context

Premature Birth

2,554 studies on the registry are indexed under Premature Birth; 498 are open to participants now.

This study's enrollment of 6,838 is above the median of 112 across 777 observational studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is the lead sponsor of 416 studies on the registry; 25 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 10 (77%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Pregnant women aged 15 years and older at 18 - 36 weeks of gestation admitted with the following diagnoses:@@@1) preterm labor with intact membranes@@@2) preterm delivery without labor@@@3) PROM leading to preterm delivery@@@4) Term deliveries without labor/spontaneous labor/with chorioamnionitis/with failed labor leading to cesarean section

Inclusion criteria

Consecutive patients admitted with the following diagnoses from four different ethnic groups (Hispanic, African American, Asian, and Caucasian):

  1. Preterm labor with intact membranes and with

    1. acute inflammation;
    2. chronic villitis;
    3. vascular pathology;
    4. no identifiable lesions.
  2. Preterm delivery without labor because of the following reasons:

    1. pre-eclampsia;
    2. abruptio placentae;
    3. fetal anomalies;
    4. Other complications (e.g. automobile accidents) that necessitate immediate delivery.
  3. PROM leading to preterm delivery and with

    1. acute inflammation;
    2. chronic villitis;
    3. vascular pathology;
    4. no identifiable lesions.
  4. Term delivery without labor and no identifiable lesions.
  5. Term delivery in spontaneous labor and no identifiable lesions.
  6. Term delivery with chorioamnionitis.
  7. Term delivery with failed labor leading to ceasarean section.

Exclusion criteria

EXCLUSION CRITERIA:

  1. Refusal of written informed consent
  2. Fetal or maternal conditions mandating immediate delivery (i.e. fetal distress, significant hemorrhage, etc.)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
6,838 participants (actual)

Groups and cohorts

  • Pregnant Women

    Consecutive pregnant women admitted with either: Preterm labor/delivery/PROM. Termdelivery without labor/spontaneous labor /chorioamnionitis/failed labor leading to c-section

06

What researchers measure

Primary outcomes

  1. To identify genes that are up- or down-regulated in preterm delivery and preterm PROM using microarray expression profiling.

    Investigate the basic mechanisms of preterm labor by systematically cataloging the changes in expression levels of all expressed genes whose sequences are available.

    Time frame: After the study is closed to accrual

07

Study locations

4 sites
  • Wayne State University
    Detroit, Michigan 48201, United States
  • Sotero del Rio Hospital
    Puente Alto, Chile
  • Padova Hospital
    Padova, Italy
  • Seoul National University
    Seoul, Korea, Republic of
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00342277
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Responsible party
Sponsor
First posted
Jun 21, 2006
Start date
Dec 21, 1999
Primary completion
May 5, 2016
Completion
May 5, 2016
Last update
Feb 24, 2023

Study contacts

Roberto Romero, M.D.
principal investigator · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion